about
Ferrocene-based antimalarialsLight-induced catalytic and cytotoxic properties of phosphorescent transition metal compounds with a d8 electronic configurationStructurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase InhibitorsDevelopment of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core LigandsAn Organometallic Inhibitor for the Human Repair Enzyme 7,8-Dihydro-8-oxoguanosine TriphosphataseBioactive cyclometalated phthalimides: design, synthesis and kinase inhibitionNon-ATP-Mimetic Organometallic Protein Kinase InhibitorCytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivativesAntimalarial activity and mechanisms of action of two novel 4-aminoquinolines against chloroquine-resistant parasitesHydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsCytotoxic hydrophilic iminophosphorane coordination compounds of d⁸ metals. Studies of their interactions with DNA and HSA.Ferrocenes as potential chemotherapeutic drugs: synthesis, cytotoxic activity, reactive oxygen species production and micronucleus assayWater-soluble oxoglaucine-Y(III), Dy(III) complexes: in vitro and in vivo anticancer activities by triggering DNA damage, leading to S phase arrest and apoptosis.DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.Structure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.Influence of substituents on DNA and protein binding of cyclometalated Ir(iii) complexes and anticancer activity.A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?In-Cell Activation of Organo-Osmium(II) Anticancer Complexes.Expression proteomics study to determine metallodrug targets and optimal drug combinations.An organometallic structure-activity relationship study reveals the essential role of a Re(CO)3 moiety in the activity against gram-positive pathogens including MRSA.Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties.Metal complexes as potential modulators of inflammatory and autoimmune responses.Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles.Enhanced Cytotoxicity through Conjugation of a "Clickable" Luminescent Re(I) Complex to a Cell-Penetrating LipopeptideSynthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors.Exploiting oxidative microenvironments in the body as triggers for drug delivery systems.Rhenium Complexes with Red-Light-Induced Anticancer Activity.Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.Heterometallic platinum(II) compounds with β-aminoethylferrocenes: synthesis, electrochemical behaviour and anticancer activity.Ruthenium(II) arene complexes with chelating chloroquine analogue ligands: synthesis, characterization and in vitro antimalarial activity.Crystal structure of 1-ferrocenyl-2-(4-methyl-benzo-yl)spiro-[11H-pyrrolidizine-3,11'-indeno[1,2-b]quinoxaline].Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.Novel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.Titanocene / cyclodextrin supramolecular systems: a theoretical approach.The potent oxidant anticancer activity of organoiridium catalysts.Mirror-image organometallic osmium arene iminopyridine halido complexes exhibit similar potent anticancer activity.New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.Cytotoxicity of cyclometalated platinum complexes based on tridentate NCN and CNN-coordinating ligands: remarkable coordination dependence.Synthesis, characterization, in vitro cytotoxicity, and apoptosis-inducing properties of ruthenium(II) complexes.
P2860
Q21032535-210DB9F9-A81A-4314-9063-ED3E98B5C131Q26823391-AE1DDAF2-6FF1-4F4D-9311-0430EFF9201DQ27667351-BAE5C56E-AEB0-4CAF-A88E-CEE24FCB2A41Q27678627-7408020C-C935-49ED-9C6A-D077362342CAQ27680660-1DD3FEF6-3451-4A2F-B0F9-751951652A3CQ27681382-CB090BA2-BED0-4AF3-A7C3-4297078FE0BAQ27681838-62320E67-7A7B-4D7F-872F-FF9B2E099C12Q27702884-F2811DE1-DE34-4DD2-A27F-9256656F6092Q28483905-42FBB744-84BE-47BA-A236-039B1EAE1E04Q28834484-489F9948-671B-4576-8E44-5545B5EEBC1CQ30573290-20924DA5-3CE6-4460-A55C-8053DFFDED62Q30882588-2583222D-DFB2-44CB-A993-1407667AAD22Q30959736-995D6B72-13A9-4297-8092-79203B16969BQ31043552-22343482-CB87-444C-8820-1B9E17D23B1EQ31119195-EC5FAECE-5113-48FC-A69A-0AF72AAA52B4Q32174625-14E5B8E7-8C96-4C0F-BFE6-2A9299078C30Q33552144-A6BDEC22-2A20-4382-9917-537D01BAB2C6Q33626165-4D6C5FF7-3337-4277-A827-3B6410636066Q33685955-42A793A5-FF45-4782-BF57-56945FE6BA2CQ33691622-D72C7D3A-E892-4E38-9661-43FA22A0FFE0Q33696556-6F34F93C-304E-48BB-AA5C-3EEC870F3502Q33805225-3872C47C-75B4-4B7F-A18B-017B05052E7AQ33862903-5537F2E9-D944-4567-A6F9-DCCCC7F2F8C7Q33889086-3CF2FBA5-C60A-476A-84BD-938C519664FEQ33900124-57E4F8BC-50D1-401F-99A7-BF8AF00A19EAQ33901754-78DF0978-97AC-4658-B67D-B2B0AEC79A17Q33919088-38FD5065-97D5-4B16-9199-C9AD2069D718Q33991566-D0606D62-0DD9-40D2-B5DC-9B043D8501BCQ34057015-7BD41707-2DED-47BE-A9A6-7D0052ED6E83Q34128946-3B4BC1B8-C7A8-4748-BA3C-E8B26F61F76BQ34291379-47BF64BD-B1EC-4396-B2FC-4EBCFA694AF3Q34327703-0F0E75A2-464C-4DBC-8548-569D8A749B1CQ34331245-5E4644F0-5409-498C-9E76-1BB7CC6E7904Q34415646-0932BDFB-E261-444B-B0C8-DCB4AB712BE5Q34466024-A3A77F33-21CC-4D95-BE71-E26DE5027085Q34488624-B66FF198-BD7F-4B6D-86DC-C7731B1496EAQ34795234-08249F45-0B40-4A8D-B872-7AB85B61E527Q35029887-752F1F27-7A36-4C56-8674-633B0E33E859Q35095042-9DF102F0-2116-4368-BB82-A337C1BC57D2Q35164388-5F4CBABB-C982-4720-8E9F-7BC580306D01
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Organometallic anticancer compounds
@ast
Organometallic anticancer compounds
@en
Organometallic anticancer compounds
@nl
type
label
Organometallic anticancer compounds
@ast
Organometallic anticancer compounds
@en
Organometallic anticancer compounds
@nl
prefLabel
Organometallic anticancer compounds
@ast
Organometallic anticancer compounds
@en
Organometallic anticancer compounds
@nl
P2093
P2860
P50
P356
P1476
Organometallic anticancer compounds
@en
P2093
Gilles Gasser
Nils Metzler-Nolte
P2860
P356
10.1021/JM100020W
P407
P577
2010-11-15T00:00:00Z